Recent therapies that increase GLP-1 activity, by the use of degradation-resistant mimetics or inhibition of GLP-1 cleavage by dipeptidyl peptidase IV, improve glycaemia in patients with type 2 diabetes, demonstrating the success of targeting the GLP-1 axis. The gene discussed is GCG; the disease is type 2 diabetes mellitus.